retatrutide type 2 diabetes trial 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide Blood Sugar Results: 2.02%

Conclusion GLP-1 RAs and dual GIP/GLP-1 RAs are highly effective treatment options for T2DM and obesity

Weeks three and four show more pronounced weight loss for most users, typically one to two pounds per week as calorie reduction compounds

The meta-analysis distils the average effect across diverse conditions providing a more generalisable estimate of what a typical patient might expect

Current evidence from large-scale clinical trials and post-marketing surveillance has not shown an increased risk of deep vein thrombosis (DVT) or pulmonary embolism (PE) with these medications

For example, obese patients given 500 mg thrice daily for 12 weeks achieved significant improvements: 5 lbs weight loss and a 23% reduction in triglycerides with a 12% drop in total cholesterol